Aurinia Pharmaceuticals Inc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Edmonton, AB. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $283 million and a profit of $287 million (its filed statements).
Product businessPharmaceutical PreparationsEdmonton, ABfilings since 20149 of 9 filed
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.8 out of ten, 9 of 9 metrics filed: past 8.0 out of ten, present 6.8 out of ten, future 5.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 7.5 out of ten. +150% a year over 8 filed years; profitable in 2 of 8. 75th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 8.7 out of ten. Share count shrank 0.8% a year. 94% of cash flow returned. Insiders: 2 sales, 11 purchases. 87th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Financial health (present): 8.1 out of ten. ROE 49%: 49¢ of profit per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar. 81st percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 8.0 out of ten. top 20% of 314 in its family; net margin 101.5%. 80th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 2.3 out of ten. bottom 23% of 315 in its family for leadership; chief executive since 2026. 23rd percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.5 out of ten. top 45% of 272 in its family for room to expand. 55th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.5 out of ten. bottom 46% of 307 in its family for growth drivers. 46th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 234 in its family for expectations against reality. 69th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-09-11. Filings on record since 2014. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Product 96%, License Collaboration and Royalty Revenue 4%. By geography: United States 93%, Japan 7%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Tang, Kevin (Chief Executive Officer); Greenleaf, Peter (Chief Executive Officer); Hearne, Michael S (Chief Financial Officer); Miller, Joseph M (Chief Financial Officer); Cole, Ryan (Chief Operating Officer); Donley, Matthew Maxwell (Chief Operating Officer); Robertson, Stephen P. (Chief Legal Officer); Keenan, Greg (SVP, Chief Medical Officer); Bailey, Jeffrey Allen (director); Goetz, Kathleen (director); and 2 more. 12 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.